Medicinal Products

EPIRUBICINE EBEWE 2 mg / ml solution for infusion vial (glass) 100 ml

Generic drug of the therapeutic class: Oncology and Hematology
Active ingredients: Epirubicin
laboratory: Sandoz

Injection solution for IV infusion
All forms

Indication

Therapeutic indications are limited to:
- breast carcinomas,
- ovarian cancers,
- non-Hodgkin's malignant lymphoma, Hodgkin's disease,
- microcellular cancers of the lung,
- soft tissue sarcomas,
- cancers of the esophagus, stomach, pancreas, hepatocellular cancers,
- squamous cell carcinoma of the otorhinolaryngological sphere.

Dosage EPIRUBICINE EBEWE 2 mg / ml solution for infusion bottle (glass) of 100 ml

Therapeutic indications are limited to:
- breast carcinomas,
- ovarian cancers,
- non-Hodgkin's malignant lymphoma, Hodgkin's disease,
- microcellular cancers of the lung,
- soft tissue sarcomas,
- cancers of the esophagus, stomach, pancreas, hepatocellular cancers,
- squamous cell carcinoma of the otorhinolaryngological sphere.

Against indications

CONTRAINDICATED:
This medicine is contraindicated in the following cases:
- Pregnancy.
- Breastfeeding.
- Subjects with cardiopathy with myocardial insufficiency.
- Major cardiac toxicity induced by anthracyclines.
- In combination with yellow fever vaccine.
NOT RECOMMENDED :
This drug is generally not recommended in combination with live attenuated vaccines other than yellow fever vaccine, phenytoin and fosphenytoin.

Adverse effects Epirubicin Ebewe

- Transient and reversible upon discontinuation of treatment:
. medullary hypoplasia,
. digestive intolerance (anorexia, nausea, vomiting),
. asthenia,
. febrile access,
. stomatitis,
. amenorrhea, azoospermia,
. alopecia.
- Rare cardiovascular complications: reduced ventricular ejection volume, heart failure. Heart failure usually occurs at cumulative doses above 900 mg / m².
- As with other DNA-damaging anticancer agents, myelodysplastic syndromes and acute myeloid leukemias have been observed following combination therapy including epirubicin.
- With topoisomerase II inhibitors, there has been reported a higher than expected incidence of secondary leukaemias presenting as de novo leukemias LAM2, LAM3, LAM4. Such forms may have a short latency period (from 1 to 3 years). These forms, accessible to a curative treatment, require early diagnosis and treatment adapted to curative (see section warnings and precautions for use).

Popular Posts

Category Medicinal Products, Next Article